Cargando…

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc

OBJECTIVES: We analysed the impact of different parameters on genotypic tropism testing related to clinical outcome prediction in 108 patients on maraviroc (MVC) treatment. METHODS: 87 RNA and 60 DNA samples were used. The viral tropism was predicted using the geno2pheno([coreceptor]) and T-CUP tool...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sierra, Saleta, Dybowski, J. Nikolai, Pironti, Alejandro, Heider, Dominik, Güney, Lisa, Thielen, Alex, Reuter, Stefan, Esser, Stefan, Fätkenheuer, Gerd, Lengauer, Thomas, Hoffmann, Daniel, Pfister, Herbert, Jensen, Björn, Kaiser, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430318/ https://www.ncbi.nlm.nih.gov/pubmed/25970632 http://dx.doi.org/10.1371/journal.pone.0125502

Ejemplares similares

V3 Loop Sequence Space Analysis Suggests Different Evolutionary Patterns of CCR5- and CXCR4-Tropic HIV
por: Bozek, Katarzyna, et al.
Publicado: (2009)

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis
por: Däumer, Martin, et al.
Publicado: (2011)

Ambulatory care for HIV-infected patients: differences in outcomes between hospital-based units and private practices: analysis of the RESINA cohort
por: Oette, Mark, et al.
Publicado: (2013)

Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C
por: Riemenschneider, Mona, et al.
Publicado: (2016)

Structure of HIV-1 quasi-species as early indicator for switches of co-receptor tropism
por: Dybowski, J Nikolaj, et al.
Publicado: (2010)

A simple structure-based model for the prediction of HIV-1 co-receptor tropism
por: Heider, Dominik, et al.
Publicado: (2014)

Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
por: Portsmouth, S, et al.
Publicado: (2010)

Analysis of Physicochemical and Structural Properties Determining HIV-1 Coreceptor Usage
por: Bozek, Katarzyna, et al.
Publicado: (2013)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa
por: Siddik, Abu Bakar, et al.
Publicado: (2018)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients
por: Gulick, Roy M., et al.
Publicado: (2014)

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
por: Garcia, Federico, et al.
Publicado: (2014)

Improved therapy-success prediction with GSS estimated from clinical HIV-1 sequences
por: Pironti, Alejandro, et al.
Publicado: (2014)

An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data
por: Bozek, Katarzyna, et al.
Publicado: (2012)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data
por: Döring, Matthias, et al.
Publicado: (2018)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

A7 Co-receptor tropism determined by genotypic assay in HIV-1 non-B subtypes circulating in Cuba: Implications for pathogenesis and Maraviroc resistance
por: Méndez, M, et al.
Publicado: (2019)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
por: Jubb, Becky, et al.
Publicado: (2019)

Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
por: Weisser, Hendrik, et al.
Publicado: (2010)

Prediction of Co-Receptor Usage of HIV-1 from Genotype
por: Dybowski, J. Nikolaj, et al.
Publicado: (2010)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency
por: Karlsson, Ulf, et al.
Publicado: (2016)

SHIVA - a web application for drug resistance and tropism testing in HIV
por: Riemenschneider, Mona, et al.
Publicado: (2016)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Using drug exposure for predicting drug resistance – A data-driven genotypic interpretation tool
por: Pironti, Alejandro, et al.
Publicado: (2017)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data
por: Pironti, Alejandro, et al.
Publicado: (2017)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms
por: Knops, Elena, et al.
Publicado: (2018)

Longitudinal comparison of HIV-1 plasma viral load and cellular proviral load
por: Schweitzer, Finja, et al.
Publicado: (2014)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kuu0sst2tigui4bt7ck3alg1rn